Osteoporosis: now and the future

TD Rachner, S Khosla, LC Hofbauer - The Lancet, 2011 - thelancet.com
Osteoporosis is a common disease characterised by a systemic impairment of bone mass
and microarchitecture that results in fragility fractures. With an ageing population, the …

New insights into osteoclast biology

MM McDonald, AS Kim, BS Mulholland, M Rauner - JBMR plus, 2021 - Wiley Online Library
Osteoclasts are multinucleated cells that are characterized by their unique ability to resorb
large quantities of bone. Therefore, they are frequently the target of therapeutic interventions …

Management of osteoporosis in men: a narrative review

F Vescini, I Chiodini, A Falchetti, A Palermo… - International Journal of …, 2021 - mdpi.com
Male osteoporosis is a still largely underdiagnosed pathological condition. As a
consequence, bone fragility in men remains undertreated mainly due to the low screening …

Targeting Fyn kinase in Alzheimer's disease

HB Nygaard - Biological psychiatry, 2018 - Elsevier
The past decade has brought tremendous progress in unraveling the pathophysiology of
Alzheimer's disease (AD). While increasingly sophisticated immunotherapy targeting soluble …

The osteoclast, bone remodelling and treatment of metabolic bone disease

BF Boyce, E Rosenberg, AE de Papp… - European journal of …, 2012 - Wiley Online Library
Eur J Clin Invest 2012; 42 (12): 1332–1341 Abstract Background Bone remodelling
maintains skeletal integrity by osteoclasts removing foci of damaged bone and osteoblasts …

Steps in prostate cancer progression that lead to bone metastasis

JK Jin, F Dayyani, GE Gallick - International journal of cancer, 2011 - Wiley Online Library
Prostate cancer is a complex disease in which metastasis to the bone is the main cause of
death. Initial stages of metastasis are generally similar to those for most solid tumors; …

A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease

HB Nygaard, AF Wagner, GS Bowen, SP Good… - Alzheimer's research & …, 2015 - Springer
Introduction Despite significant progress, a disease-modifying therapy for Alzheimer's
disease (AD) has not yet been developed. Recent findings implicate soluble oligomeric …

Fyn deficiency inhibits oxidative stress by decreasing c-Cbl-mediated ubiquitination of Sirt1 to attenuate diabetic renal fibrosis

S Li, Z Lin, H Xiao, Z Xu, C Li, J Zeng, X Xie, L Deng… - Metabolism, 2023 - Elsevier
Objective Oxidative stress (OS) is the main cause leading to diabetic renal fibrosis. Recently,
Fyn was paid much attention on OS and emerged as a pivotal player in acute kidney injury …

Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK

K Dhami, A Chakraborty, TL Gururaja, LWK Cheung… - Science …, 2022 - science.org
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib irreversibly binds BTK at Cys481,
inhibiting its kinase activity and thus blocking transduction of B cell receptor (BCR) signaling …

[HTML][HTML] Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva

E Williams, J Bagarova, G Kerr, DD Xia, ES Place… - Jci Insight, 2021 - ncbi.nlm.nih.gov
Currently, no effective therapies exist for fibrodysplasia ossificans progressiva (FOP), a rare
congenital syndrome in which heterotopic bone is formed in soft tissues owing to …